Zanolimumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Zanolimumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target CD4
Clinical data
Legal status ?
Identifiers
CAS number 652153-01-0 N
ATC code None
UNII HG3L8885M0 YesY
KEGG D06356 YesY
Chemical data
Formula ?
Mol. mass 147 kDa
 N (what is this?)  (verify)

Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials.[5]

References[edit]

  1. ^ Genmab initiates Phase II Study with HuMax-CD4
  2. ^ http://www.tenxbiopharma.com/development.shtml
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
  4. ^ ClinicalTrials.gov NCT00042406 Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker
  5. ^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.